Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Clinical Trial
Official title:
A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients With Relapsed/Refractory Glioma Positive for an FGFR Fusion
The investigators will look for the presence of the fusion gene in all patients operated on
for glioma. This search will be limited to all gliomas that show no IDH1 mutation, the latter
being sought in both routine and anomalies never co-existing.
The hypothesis is that the rate of progression-free survival in grade IV gliomas and III
without IDH1 mutation, with the usual chemotherapy, only 15% at 6 months (ie, 85% of patients
relapse before 6 months of treatment), must be with this new treatment 35% (primary
endpoint).
The main objective is the evaluation of disease-free survival at 6 months.
3% of GBM and IDHwt gliomas have a highly oncogenic FGFR-TACC gene fusion that confers high
sensitivity to FGFR inhibitors to tumor cells, in vitro and in vivo. Preclinical data shows
that expression of FGFR-TACC fusions confers sensitivity to FGFR inhibitors (including
AZD4547) to GBM models.AZD4547 (AstraZeneca) is a potent and selective inhibitor of FGFR-1, 2
and 3 receptor tyrosine kinases. Preclinical data have shown some CNS penetration. Some of
the important adverse events are hyperphosphatemia, and ocular complications. The primary
objective and assessment criterion is to assess the efficacy of AZD4547 by measuring the rate
of Progression Free Survival at 6 months (PFS6) in recurrent malignant glioma patients with
FGFR-TACC fusion.Secondary objectives and assessment criteria are: - To characterize the
safety, tolerability and PK of AZD4547 in glioma patients
- To further assess the anti-tumor activity of AZD4547 for patients with recurrent glioma
with FGFR-TACC fusion based on Overall Response Rate for patients with a measurable
residue.
- To further assess the anti-tumor activity of AZD4547 for patients with recurrent glioma
with FGFR-TACC fusion based on the duration of PFS
- To further assess the anti-tumor activity of AZD4547 for patients with recurrent glioma
with a FGFR-TACC fusion based on Overall Survival AZD4547 Exploratory objectives - To
elucidate the mechanism of response and resistance (primary and secondary) by
exploratory biomarker analysis Experimental design: This is a phase II study in patients
diagnosed with a FGFR3-TACC3 or FGFR1-TACC1 fusion positive glioma presenting with a
recurrence of the disease after chemotherapy and radiotherapy. RNA will be
systematically screened for the presence of FGFR-TACC in each of the 11 participating
centers, and IHC for FGFR3 hyperexpression. The investigators also encourage a wide use
of FGFR3 IHC in non participating centers in order to identify additional potential
candidates who can be referred to one of the 11 centers for assessment of FGFR-TACC
expression by RNA analysis..
Patients will receive AZD4547 at a dose of 80mg bd on a continuous schedule, until disease
progression. With the following hypothesis: P0: PFS6=15%, P1: PFS6=35%, with alpha=5% and
power=80%, an initial cohort of 12 patients will be treated. If objective anti-tumor effects
are observed, the cohort will be expanded to include a total number of 38 subjects. Grade II
gliomas are also eligible but they will constitute an extra small cohort.
;